Renaissance Technologies LLC Raises Stake in Omnicell, Inc. (NASDAQ:OMCL)

Renaissance Technologies LLC boosted its holdings in Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 79.3% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 456,343 shares of the company's stock after buying an additional 201,831 shares during the quarter. Renaissance Technologies LLC owned approximately 0.99% of Omnicell worth $20,316,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Geode Capital Management LLC increased its position in Omnicell by 0.3% in the 3rd quarter. Geode Capital Management LLC now owns 1,104,745 shares of the company's stock valued at $48,176,000 after acquiring an additional 2,877 shares during the period. Shaker Investments LLC OH acquired a new stake in Omnicell in the fourth quarter valued at $550,000. Empowered Funds LLC acquired a new stake in Omnicell in the fourth quarter valued at $388,000. Exchange Traded Concepts LLC raised its position in Omnicell by 6.7% during the 4th quarter. Exchange Traded Concepts LLC now owns 319,682 shares of the company's stock worth $14,232,000 after purchasing an additional 20,031 shares during the last quarter. Finally, SG Americas Securities LLC lifted its holdings in Omnicell by 56.5% during the 4th quarter. SG Americas Securities LLC now owns 39,359 shares of the company's stock worth $1,752,000 after buying an additional 14,202 shares during the period. Institutional investors own 97.70% of the company's stock.

Analysts Set New Price Targets

Several brokerages have recently weighed in on OMCL. Bank of America lowered their price objective on Omnicell from $54.00 to $46.00 and set a "neutral" rating for the company in a research report on Monday, January 6th. StockNews.com raised shares of Omnicell from a "hold" rating to a "buy" rating in a research note on Tuesday. Wells Fargo & Company lowered their target price on shares of Omnicell from $40.00 to $38.00 and set an "equal weight" rating for the company in a research note on Thursday. JPMorgan Chase & Co. cut their price target on shares of Omnicell from $44.00 to $36.00 and set a "neutral" rating on the stock in a research report on Thursday, March 20th. Finally, Benchmark reissued a "buy" rating and issued a $62.00 price objective on shares of Omnicell in a research note on Tuesday, February 4th. Four investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $50.67.

Omnicell Stock Down 2.2 %

Shares of Omnicell stock traded down $0.68 during trading hours on Thursday, reaching $30.27. The company's stock had a trading volume of 513,838 shares, compared to its average volume of 531,547. The company has a market capitalization of $1.42 billion, a P/E ratio of 112.10, a P/E/G ratio of 7.53 and a beta of 0.78. The stock's fifty day simple moving average is $35.74 and its two-hundred day simple moving average is $41.45. Omnicell, Inc. has a one year low of $25.12 and a one year high of $55.75. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.22 and a current ratio of 1.37.

Omnicell (NASDAQ:OMCL - Get Free Report) last issued its quarterly earnings data on Thursday, February 6th. The company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.57 by ($0.12). Omnicell had a return on equity of 3.82% and a net margin of 1.13%. On average, research analysts forecast that Omnicell, Inc. will post 1.09 earnings per share for the current year.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.